The global clinical oncology next generation sequencing market size is calculated at USD 642 million in 2024 and is predicted to reach around USD 3,194 million by 2034, expanding at a CAGR of 17.4% from 2024 to 2034.
Clinical oncology next generation sequencing market growth is attributed to the growing competition among players, the rise in the prevalence of cancer, the rising technological advancements and increasing healthcare spending. In addition, the increasing research and development activities to invent solutions is anticipated to drive the market growth. The guidelines and regulations necessary by several economics' governments for cancer treatment have driven the market growth.
In addition, the growing adoption of companion personalized medicine and diagnostics, the rising technological advancements in next generation sequencing, the rising usage of NGS for liquid biopsy, increasing market competition and the increase in clinical applications of NGS in precision oncology are further anticipated to enhance the growth of the clinical oncology next generation sequencing market during the forecast period.
Published by Ajit Bansod
